Compare Eli Lilly And Co (LLY) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B). The key difference: Eli Lilly And Co is far larger — about 13.4× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| LLY | MDLZ | |
|---|---|---|
Market Cap | $1.04T | $77.43B |
Volume | 3,064,878 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $64.99 |
52-Week Low | $799.57 | $51.51 |
Typical Hold Time | 93 Days | 107 Days |
Enterprise Value | $1.09T | $97.78B |
Dividend Yield | 0.59% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.73 exceeding expectations. Revenue growth continues, reaching $38.54B in 2025, while maintaining solid profitability with 8.86% net margin. Recent dividend increase to $0.52 per share and positive news coverage highlight management's confidence in sustained performance.
MDLZ presents a compelling investment case with 76% analyst buy ratings and $70.29 consensus target, offering 16% upside. The company's global brand strength and emerging market momentum support growth, though cocoa cost pressures and competitive snack market pose risks. Cash flow stability and shareholder returns through dividends provide defensive characteristics in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
